-
2
-
-
0000905251
-
Therapeutic strategies in Parkinson's disease
-
Jankovic J, Tolosa E, editors. Baltimore: Williams & Wilkins
-
Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1993: 115-44
-
(1993)
Parkinson's Disease and Movement Disorders
, pp. 115-144
-
-
Jankovic, J.1
Marsden, C.D.2
-
3
-
-
0029337643
-
Pharmacokinetic optimisation of drug therapy in elderly patients
-
Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
-
(1995)
Drugs Aging
, vol.7
, pp. 10-18
-
-
Parker, B.M.1
Cusack, B.J.2
Vestal, R.E.3
-
5
-
-
0022551086
-
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography
-
Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60
-
(1986)
J Neurol Neurosurg Psychiatry
, vol.49
, pp. 853-860
-
-
Leenders, K.L.1
Palmer, A.J.2
Quinn, N.3
-
6
-
-
0026569502
-
Cerebral uptake and utilization of therapeutic beta-11C-L-dopa in Parkinson's disease measured by positron emission tomography. Relations to motor response
-
Tedroff J, Aquilonius SM, Hartvig P, et al. Cerebral uptake and utilization of therapeutic beta-11C-L-dopa in Parkinson's disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand 1992; 85: 95-102
-
(1992)
Acta Neurol Scand
, vol.85
, pp. 95-102
-
-
Tedroff, J.1
Aquilonius, S.M.2
Hartvig, P.3
-
7
-
-
0028172598
-
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
-
Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36: 759-64
-
(1994)
Ann Neurol
, vol.36
, pp. 759-764
-
-
Vingerhoets, F.J.G.1
Snow, B.J.2
Lee, C.S.3
-
8
-
-
0023521931
-
On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
-
Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535-40
-
(1987)
Ann Neurol
, vol.22
, pp. 535-540
-
-
Nutt, J.G.1
-
9
-
-
0016724743
-
Intestinal decarboxylation of orally administered L-dopa
-
Andersson I, Granerus AK, Jagenburg R, et al. Intestinal decarboxylation of orally administered L-dopa. Acta Med Scand 1975; 198: 415-20
-
(1975)
Acta Med Scand
, vol.198
, pp. 415-420
-
-
Andersson, I.1
Granerus, A.K.2
Jagenburg, R.3
-
10
-
-
0017197009
-
Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of Parkinsonism
-
Pinder RM, Brogden RN, Sawyer PR, et al. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism. Drugs 1976; 11: 329-77
-
(1976)
Drugs
, vol.11
, pp. 329-377
-
-
Pinder, R.M.1
Brogden, R.N.2
Sawyer, P.R.3
-
11
-
-
0014467068
-
Drug-induced changes of extracerebral dopa metabolism in man
-
Tissot R, Bartholini G, Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol 1969; 20: 187-90
-
(1969)
Arch Neurol
, vol.20
, pp. 187-190
-
-
Tissot, R.1
Bartholini, G.2
Pletscher, A.3
-
12
-
-
0024393058
-
The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa
-
Robertson DRC, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmucol 1989; 28: 61-9
-
(1989)
Br J Clin Pharmucol
, vol.28
, pp. 61-69
-
-
Robertson, D.R.C.1
Wood, N.D.2
Everest, H.3
-
13
-
-
0018858058
-
Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa
-
Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. Arch Neurol 1980; 37: 146-9
-
(1980)
Arch Neurol
, vol.37
, pp. 146-149
-
-
Hoehn, M.M.1
-
14
-
-
0022354407
-
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism
-
Bermejo Pareja F, Martinez-Martin P, Muradas V, et al. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism. Acta Neurol Scand 1985; 72: 506-11
-
(1985)
Acta Neurol Scand
, vol.72
, pp. 506-511
-
-
Bermejo Pareja, F.1
Martinez-Martin, P.2
Muradas, V.3
-
15
-
-
0022590163
-
Effect of supplemental carbidopa on bioavailability of L-dopa
-
Cedarbaum JM, Kutt H, Dhar AK, et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986; 9: 153-9
-
(1986)
Clin Neuropharmacol
, vol.9
, pp. 153-159
-
-
Cedarbaum, J.M.1
Kutt, H.2
Dhar, A.K.3
-
16
-
-
0347206174
-
Clinical studies of carbidopa and l-dopa in the treatment of Parkinson's disease
-
Yahr MD, editor. New York: Raven Press
-
Jaffe ME. Clinical studies of carbidopa and l-dopa in the treatment of Parkinson's disease. In: Yahr MD, editor. Advances in neurology. New York: Raven Press, 1973: 161-72
-
(1973)
Advances in Neurology
, pp. 161-172
-
-
Jaffe, M.E.1
-
17
-
-
0019156918
-
Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease
-
Tourtellotte JW, Syndulko K, Potvin AR, et al. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease. Arch Neurol 1980; 37: 723-6
-
(1980)
Arch Neurol
, vol.37
, pp. 723-726
-
-
Tourtellotte, J.W.1
Syndulko, K.2
Potvin, A.R.3
-
18
-
-
0018639137
-
Levodopa with benserazide or carbidopa in Parkinson disease
-
Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979; 29: 1584-9
-
(1979)
Neurology
, vol.29
, pp. 1584-1589
-
-
Rinne, U.K.1
Molsa, P.2
-
19
-
-
0028954916
-
International guide to drugs for Parkinson's disease
-
Oertel WH, Dodel RC. International guide to drugs for Parkinson's disease. Mov Disord 1995; 10: 121-31
-
(1995)
Mov Disord
, vol.10
, pp. 121-131
-
-
Oertel, W.H.1
Dodel, R.C.2
-
20
-
-
0015922208
-
Active transport of L-dopa in the intestine
-
Wade DN, Mearrick PT, Morris J. Active transport of L-dopa in the intestine. Nature 1973; 242: 463-5
-
(1973)
Nature
, vol.242
, pp. 463-465
-
-
Wade, D.N.1
Mearrick, P.T.2
Morris, J.3
-
21
-
-
0014940306
-
L-dopa treatment failure: Explanation and correction
-
Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. L-dopa treatment failure: explanation and correction. BMJ 1970; 4: 93-4
-
(1970)
BMJ
, vol.4
, pp. 93-94
-
-
Rivera-Calimlim, L.1
Dujovne, C.A.2
Morgan, J.P.3
-
22
-
-
0021359568
-
The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport
-
Nutt JG, Woodward WR, Hammerstad JP, et al. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483-8
-
(1984)
N Engl J Med
, vol.310
, pp. 483-488
-
-
Nutt, J.G.1
Woodward, W.R.2
Hammerstad, J.P.3
-
23
-
-
0023522470
-
Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients
-
Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37
-
(1987)
Clin Neuropharmacol
, vol.10
, pp. 527-537
-
-
Baruzzi, A.1
Contin, M.2
Riva, R.3
-
24
-
-
0017225588
-
Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man
-
Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man. Eur J Clin Pharmacol 1976; 35: 293-9
-
(1976)
Eur J Clin Pharmacol
, vol.35
, pp. 293-299
-
-
Algeri, S.1
Cerletti, C.2
Curcio, M.3
-
25
-
-
0026070503
-
Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: Effect on levodopa bioavailability
-
Contin M, Riva R, Martinelli P, et al. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: effect on levodopa bioavailability. Clin Neuropharmacol 1991; 14: 148-55
-
(1991)
Clin Neuropharmacol
, vol.14
, pp. 148-155
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
26
-
-
0016743254
-
Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man
-
Morgan JP, Rivera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029-34
-
(1975)
Neurology
, vol.25
, pp. 1029-1034
-
-
Morgan, J.P.1
Rivera-Calimlim, L.2
Messiha, F.3
-
27
-
-
0025888930
-
Gastric emptying in healthy volunteers after multiple doses of levodopa
-
Waller DG, Roseveare C, Renwick AG, et al. Gastric emptying in healthy volunteers after multiple doses of levodopa. Br J Clin Pharmacol 1991; 32: 691-5
-
(1991)
Br J Clin Pharmacol
, vol.32
, pp. 691-695
-
-
Waller, D.G.1
Roseveare, C.2
Renwick, A.G.3
-
28
-
-
0023856314
-
Lack of pharmacokinetic influence on levodopa by bromocriptine
-
Bentuè-Ferrer D, Allain H, Reymann JM, et al. Lack of pharmacokinetic influence on levodopa by bromocriptine. Clin Neuropharmacol 1988; 11: 83-6
-
(1988)
Clin Neuropharmacol
, vol.11
, pp. 83-86
-
-
Bentuè-Ferrer, D.1
Allain, H.2
Reymann, J.M.3
-
29
-
-
0026458576
-
No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease
-
Contin M, Riva R, Martinelli P, et al. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease. Clin Neuropharmacol 1992; 15: 505-8
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 505-508
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
30
-
-
0025789844
-
The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease
-
Rabey JM, Schwartz M, Graff E, et al. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 1991; 14: 514-22
-
(1991)
Clin Neuropharmacol
, vol.14
, pp. 514-522
-
-
Rabey, J.M.1
Schwartz, M.2
Graff, E.3
-
31
-
-
0027270391
-
Blood levodopa levels and Unified Parkinson's Disease Rating Scale function: With and without exercise
-
Goetz CG, Thelen JA, MacLeod CM, et al. Blood levodopa levels and Unified Parkinson's Disease Rating Scale function: with and without exercise. Neurology 1993; 43: 1040-2
-
(1993)
Neurology
, vol.43
, pp. 1040-1042
-
-
Goetz, C.G.1
Thelen, J.A.2
MacLeod, C.M.3
-
32
-
-
0026794991
-
The effect of exercise on levodopa absorption
-
Carter JH, Nutt JG, Woodward WR. The effect of exercise on levodopa absorption. Neurology 1992; 42: 2042-5
-
(1992)
Neurology
, vol.42
, pp. 2042-2045
-
-
Carter, J.H.1
Nutt, J.G.2
Woodward, W.R.3
-
34
-
-
0025156924
-
Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations
-
Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990; 13: 19-28
-
(1990)
Clin Neuropharmacol
, vol.13
, pp. 19-28
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
35
-
-
0023185154
-
Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients
-
Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 1987; 37: 940-4
-
(1987)
Neurology
, vol.37
, pp. 940-944
-
-
Gancher, S.T.1
Nutt, J.G.2
Woodward, W.R.3
-
36
-
-
0022397679
-
The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa
-
Kaakkola S, Mannisto PT, Nissinen E, et al. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 1985; 72: 385-91
-
(1985)
Acta Neurol Scand
, vol.72
, pp. 385-391
-
-
Kaakkola, S.1
Mannisto, P.T.2
Nissinen, E.3
-
37
-
-
0026579830
-
The influence of levodopa on gastric emptying in healthy elderly volunteers
-
Robertson DRC, Renwick AG, Macklin B, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol 1992; 42: 409-12
-
(1992)
Eur J Clin Pharmacol
, vol.42
, pp. 409-412
-
-
Robertson, D.R.C.1
Renwick, A.G.2
Macklin, B.3
-
38
-
-
0028071369
-
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa
-
Verhagen Metman L, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994; 9: 463-5
-
(1994)
Mov Disord
, vol.9
, pp. 463-465
-
-
Verhagen Metman, L.1
Hoff, J.2
Mouradian, M.M.3
-
39
-
-
0022556678
-
Inhibition of 1-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography
-
Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of 1-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258-62
-
(1986)
Ann Neurol
, vol.20
, pp. 258-262
-
-
Leenders, K.L.1
Poewe, W.H.2
Palmer, A.J.3
-
40
-
-
0016425567
-
Protein intake and treatment of Parkinson's disease with levodopa
-
Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975; 292: 181-4
-
(1975)
N Engl J Med
, vol.292
, pp. 181-184
-
-
Mena, I.1
Cotzias, G.C.2
-
41
-
-
0023141842
-
Influence of dietary protein on motor fluctuations in Parkinson's disease
-
Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987; 44: 270-2
-
(1987)
Arch Neurol
, vol.44
, pp. 270-272
-
-
Pincus, J.H.1
Barry, K.2
-
42
-
-
0023433165
-
Plasma levels of amino acids correlate with motor fluctuations in Parkinsonism
-
Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in Parkinsonism. Arch Neurol 1987; 44: 1006-9
-
(1987)
Arch Neurol
, vol.44
, pp. 1006-1009
-
-
Pincus, J.H.1
Barry, K.M.2
-
43
-
-
0025772989
-
A balanced carbohydrate: Protein diet in the management of Parkinson's disease
-
Berry EM, Growdon JH, Wurtman JJ, et al. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991; 41: 1295-7
-
(1991)
Neurology
, vol.41
, pp. 1295-1297
-
-
Berry, E.M.1
Growdon, J.H.2
Wurtman, J.J.3
-
44
-
-
0003673876
-
-
Washington, DC: National Academy Press
-
Committee on dietary allowances food and nutrition board, editor. Recommended dietary allowances. Washington, DC: National Academy Press, 1989
-
(1989)
Recommended Dietary Allowances
-
-
-
45
-
-
0023429272
-
Dietary influences on the antiparkinsonian response to levodopa
-
Juncos JL, Fabbrini G, Mouradian MM, et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987; 44: 1003-5
-
(1987)
Arch Neurol
, vol.44
, pp. 1003-1005
-
-
Juncos, J.L.1
Fabbrini, G.2
Mouradian, M.M.3
-
47
-
-
0016829492
-
Catechol-O-methyl transferase: Pharmacological aspects and physiological role
-
Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206
-
(1975)
Pharmacol Rev
, vol.27
, pp. 135-206
-
-
Guldberg, H.C.1
Marsden, C.A.2
-
48
-
-
0015302499
-
3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral l-dopa therapy of patients with Parkinson's disease
-
Sharpless NS, Muenter MD, Tyce GM, et al. 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral l-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 1972; 37: 359-69
-
(1972)
Clin Chim Acta
, vol.37
, pp. 359-369
-
-
Sharpless, N.S.1
Muenter, M.D.2
Tyce, G.M.3
-
49
-
-
0016686587
-
Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine
-
Pilling JB, Baker J, Iversen LL, et al. Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine. J Neurol Neurosurg Psychiatry 1975; 38: 129-35
-
(1975)
J Neurol Neurosurg Psychiatry
, vol.38
, pp. 129-135
-
-
Pilling, J.B.1
Baker, J.2
Iversen, L.L.3
-
50
-
-
0016707704
-
3-O-methyldopa uptake and inhibition of l-dopa at the blood-brain barrier
-
Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of l-dopa at the blood-brain barrier. Life Sci 1975; 17: 131-6
-
(1975)
Life Sci
, vol.17
, pp. 131-136
-
-
Wade, L.A.1
Katzman, R.2
-
51
-
-
0019985169
-
3-O-methyldopa blocks dopa metabolism in rat corpus striatum
-
Reches A, Fahn S. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 1982; 12: 267-71
-
(1982)
Ann Neurol
, vol.12
, pp. 267-271
-
-
Reches, A.1
Fahn, S.2
-
52
-
-
0020685128
-
Effects of 3-OM-dopa on monoamine metabolism in rat brain
-
Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983; 33: 278-82
-
(1983)
Neurology
, vol.33
, pp. 278-282
-
-
Gervas, J.J.1
Muradas, V.2
Bazan, E.3
-
53
-
-
0023265840
-
3-O-methyldopa and the response to levodopa in Parkinson's disease
-
Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8
-
(1987)
Ann Neurol
, vol.21
, pp. 584-588
-
-
Nutt, J.G.1
Woodward, W.R.2
Gancher, S.T.3
-
54
-
-
0026724717
-
3-O-methyldopa administration does not alter fluorodopa transport into the brain
-
Guttman M, Leger G, Cedarbaum JM, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992; 31: 638-43
-
(1992)
Ann Neurol
, vol.31
, pp. 638-643
-
-
Guttman, M.1
Leger, G.2
Cedarbaum, J.M.3
-
55
-
-
0024521415
-
Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet
-
Nelson MV, Berchou RC, Lewitt PA, et al. Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol 1989; 12: 91-7
-
(1989)
Clin Neuropharmacol
, vol.12
, pp. 91-97
-
-
Nelson, M.V.1
Berchou, R.C.2
Lewitt, P.A.3
-
56
-
-
0025000599
-
Pharmacokinetics and effects of levodopa in advanced Parkinson's disease
-
Bredberg E, Tedroff J, Aquilonius SM, et al. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990; 39: 385-9
-
(1990)
Eur J Clin Pharmacol
, vol.39
, pp. 385-389
-
-
Bredberg, E.1
Tedroff, J.2
Aquilonius, S.M.3
-
57
-
-
0025988169
-
Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease
-
Contin M, Riva R, Martinelli P, et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 463-6
-
(1991)
Eur J Clin Pharmacol
, vol.41
, pp. 463-466
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
58
-
-
0025149525
-
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease
-
Campbell NRC, Rankine D, Goodridge AE, et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605
-
(1990)
Br J Clin Pharmacol
, vol.30
, pp. 599-605
-
-
Campbell, N.R.C.1
Rankine, D.2
Goodridge, A.E.3
-
59
-
-
0015043830
-
L-dopa therapy of Parkinson's disease: Plasma l-dopa concentration, therapeutic response, and side effects
-
Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma l-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231-9
-
(1971)
Mayo Clin Proc
, vol.46
, pp. 231-239
-
-
Muenter, M.D.1
Tyce, G.M.2
-
60
-
-
0020059227
-
Alternate day levodopa therapy in parkinsonism
-
Koller WC. Alternate day levodopa therapy in parkinsonism. Neurology 1982; 32: 324-6
-
(1982)
Neurology
, vol.32
, pp. 324-326
-
-
Koller, W.C.1
-
61
-
-
0027212443
-
Oral pulse levodopa therapy in mild Parkinson's disease
-
Quattrone A, Zappia M. Oral pulse levodopa therapy in mild Parkinson's disease. Neurology 1993; 43: 1161-6
-
(1993)
Neurology
, vol.43
, pp. 1161-1166
-
-
Quattrone, A.1
Zappia, M.2
-
62
-
-
0026466318
-
Optimization of levodopa therapy
-
Pfeiffer R. Optimization of levodopa therapy. Neurology 1992: 42 Suppl. 1; 39-43
-
(1992)
Neurology
, vol.42
, Issue.1 SUPPL.
, pp. 39-43
-
-
Pfeiffer, R.1
-
63
-
-
0026466358
-
Initiating treatment of Parkinson's disease
-
Koller WC. Initiating treatment of Parkinson's disease. Neurology 1992; 42 Suppl. 1; 33-8
-
(1992)
Neurology
, vol.42
, Issue.1 SUPPL.
, pp. 33-38
-
-
Koller, W.C.1
-
64
-
-
0001205759
-
Practical guidelines for the drug treatment of Parkinson's disease
-
Mizuno Y, Mori H, Kondo T. Practical guidelines for the drug treatment of Parkinson's disease. CNS Drugs 1994; 1: 410-26
-
(1994)
CNS Drugs
, vol.1
, pp. 410-426
-
-
Mizuno, Y.1
Mori, H.2
Kondo, T.3
-
65
-
-
0027930341
-
Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
-
Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994; 44: 1287-92
-
(1994)
Neurology
, vol.44
, pp. 1287-1292
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
66
-
-
0029982987
-
Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease
-
Contin M, Riva R, Martinelli P, et al. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 1996; 46: 1055-8
-
(1996)
Neurology
, vol.46
, pp. 1055-1058
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
67
-
-
0023127020
-
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
-
Fabbrini G, Juncos JL, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987; 21: 370-6
-
(1987)
Ann Neurol
, vol.21
, pp. 370-376
-
-
Fabbrini, G.1
Juncos, J.L.2
Mouradian, M.M.3
-
68
-
-
0022443805
-
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
-
Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986; 36: 739-44
-
(1986)
Neurology
, vol.36
, pp. 739-744
-
-
Nutt, J.G.1
Woodward, W.R.2
-
69
-
-
0022657221
-
Episodic unresponsiveness to single doses of l-dopa in parkinsonian fluctuators
-
Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of l-dopa in parkinsonian fluctuators. Neurology 1986; 36: 100-3
-
(1986)
Neurology
, vol.36
, pp. 100-103
-
-
Melamed, E.1
Bitton, V.2
Zelig, O.3
-
70
-
-
0023869464
-
Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility
-
Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology 1988; 38: 419-21
-
(1988)
Neurology
, vol.38
, pp. 419-421
-
-
Kurlan, R.1
Kp, R.2
Woodward, W.R.3
-
71
-
-
0027159879
-
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: A pilot study
-
Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
-
(1993)
Neurology
, vol.43
, pp. 1036-1039
-
-
Kurth, M.C.1
Tetrud, J.W.2
Irwin, I.3
-
72
-
-
0026476554
-
The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease
-
Steiger MJ, Stocchi F, Bramante L, et al. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol 1992; 15: 501-4
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 501-504
-
-
Steiger, M.J.1
Stocchi, F.2
Bramante, L.3
-
73
-
-
0028937547
-
Madopar dispersible in the treatment of advanced parkinson's disease
-
Fornadi F, Milani F, Werner M. Madopar dispersible in the treatment of advanced parkinson's disease. Clin Neuropharmacol 1994; 17 (3 Suppl.): 7S-15S
-
(1994)
Clin Neuropharmacol
, vol.17
, Issue.3 SUPPL.
-
-
Fornadi, F.1
Milani, F.2
Werner, M.3
-
74
-
-
0028878429
-
The effects of cisapride on plasma l-dopa levels and clinical response in Parkinson's disease
-
Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma l-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995; 10: 66-70
-
(1995)
Mov Disord
, vol.10
, pp. 66-70
-
-
Neira, W.D.1
Sanchez, V.2
Mena, M.A.3
-
75
-
-
0028981463
-
Effect of cisapride on response fluctuations in Parkinson's disease
-
Djaldetti R, Koren M. Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995; 10: 81-4
-
(1995)
Mov Disord
, vol.10
, pp. 81-84
-
-
Djaldetti, R.1
Koren, M.2
Ziv, I.3
-
76
-
-
0024507807
-
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease
-
Carter JH, Nutt JG, Woodward WR, et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1989; 39: 552-6
-
(1989)
Neurology
, vol.39
, pp. 552-556
-
-
Carter, J.H.1
Nutt, J.G.2
Woodward, W.R.3
-
77
-
-
0023845228
-
Protein redistribution diet restores motor function in patients with dopa-resistanl 'off' periods
-
Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistanl 'off' periods. Neurology 1988: 38: 481-3
-
(1988)
Neurology
, vol.38
, pp. 481-483
-
-
Pincus, J.H.1
Barry, K.2
-
78
-
-
0023765002
-
Practical application of a low-protein diet for Parkinson's disease
-
Riley D, Lane AE. Practical application of a low-protein diet for Parkinson's disease. Neurology 1988; 38: 1026-31
-
(1988)
Neurology
, vol.38
, pp. 1026-1031
-
-
Riley, D.1
Lane, A.E.2
-
79
-
-
0028944514
-
Clinical efficacy of a liquid formulation of Levodopa (Madopar Dispersible) in reversing afternoon 'off' periods in Parkinson's disease
-
Ziegler M, Ranoux D, de Recondo J. Clinical efficacy of a liquid formulation of Levodopa (Madopar Dispersible) in reversing afternoon 'off' periods in Parkinson's disease. Clin Neuropharmacol 1994; 17 (3 Suppl.): 21S-5S
-
(1994)
Clin Neuropharmacol
, vol.17
, Issue.3 SUPPL.
-
-
Ziegler, M.1
Ranoux, D.2
De Recondo, J.3
-
80
-
-
0017840794
-
Onset and end-of-dose levodopa-induced dyskinesias
-
Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978; 35: 261-3
-
(1978)
Arch Neurol
, vol.35
, pp. 261-263
-
-
Lhermitte, F.1
Agid, Y.2
Signoret, J.L.3
-
81
-
-
0028006366
-
An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias
-
Mark MH, Sage JI. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias. Ann Clin Lab Sci 1994; 24: 12-21
-
(1994)
Ann Clin Lab Sci
, vol.24
, pp. 12-21
-
-
Mark, M.H.1
Sage, J.I.2
-
82
-
-
0022446286
-
L-dopa: How it may exacerbate parkinsonian symptoms
-
Paalzow GHM, Paalzow LK. L-dopa: how it may exacerbate parkinsonian symptoms. TIPS 1986; 9: 15-9
-
(1986)
TIPS
, vol.9
, pp. 15-19
-
-
Paalzow, G.H.M.1
Paalzow, L.K.2
-
83
-
-
0026472109
-
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease
-
Merello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 1024-6
-
(1992)
J Neurol Neurosurg Psychiatry
, vol.55
, pp. 1024-1026
-
-
Merello, M.1
Lees, A.J.2
-
84
-
-
0023729233
-
Does an inhibitory action of levodopa contribute to motor fluctuations?
-
Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1553-7
-
(1988)
Neurology
, vol.38
, pp. 1553-1557
-
-
Nutt, J.G.1
Gancher, S.T.2
Woodward, W.R.3
-
85
-
-
0026765992
-
Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease
-
Contin M, Riva R, Martinelli P, et al. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 1992; 7: 244-8
-
(1992)
Mov Disord
, vol.7
, pp. 244-248
-
-
Contin, M.1
Riva, R.2
Martinelli, P.3
-
86
-
-
0025355032
-
Levodopa-induced dyskinesia: Review, observations, and speculations
-
Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-5
-
(1990)
Neurology
, vol.40
, pp. 340-345
-
-
Nutt, J.G.1
-
87
-
-
0025818385
-
Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced Chorea
-
Sage JI, Mark MH, McHale DM, et al. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced Chorea. Ann Neurol 1991; 29: 623-8
-
(1991)
Ann Neurol
, vol.29
, pp. 623-628
-
-
Sage, J.I.1
Mark, M.H.2
McHale, D.M.3
-
88
-
-
0025321413
-
Complex dystonia of Parkinson's disease: Clinical features and relation to plasma levodopa profile
-
McHale DM, Sage JI, Sonsalla PK, et al. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990; 13: 164-70
-
(1990)
Clin Neuropharmacol
, vol.13
, pp. 164-170
-
-
McHale, D.M.1
Sage, J.I.2
Sonsalla, P.K.3
-
89
-
-
0028211054
-
Severe evening dyskinesias in advanced parkinson's disease: Clinical description, relation to plasma levodopa, and treatment
-
Zimmerman TR, Sage JI, Lang AE, et al. Severe evening dyskinesias in advanced parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Mov Disord 1994; 9: 173-7
-
(1994)
Mov Disord
, vol.9
, pp. 173-177
-
-
Zimmerman, T.R.1
Sage, J.I.2
Lang, A.E.3
-
90
-
-
0024347984
-
Pathogenesis of dyskinesias in Parkinson's disease
-
Mouradian MM, Heuser JE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989; 25: 523-6
-
(1989)
Ann Neurol
, vol.25
, pp. 523-526
-
-
Mouradian, M.M.1
Heuser, J.E.2
Baronti, F.3
-
91
-
-
0016587362
-
Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients
-
Shoulson I, Glaubiger GA, Chase TN. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144-8
-
(1975)
Neurology
, vol.25
, pp. 1144-1148
-
-
Shoulson, I.1
Glaubiger, G.A.2
Chase, T.N.3
-
92
-
-
0021211101
-
Control of on/off phenomenon by continuous intravenous infusion of levodopa
-
Quinn N, Parkes D, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131-6
-
(1984)
Neurology
, vol.34
, pp. 1131-1136
-
-
Quinn, N.1
Parkes, D.2
Marsden, C.D.3
-
93
-
-
0021142576
-
On-off fluctuations in Parkinson's disease
-
Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. Brain 1984; 107: 487-506
-
(1984)
Brain
, vol.107
, pp. 487-506
-
-
Hardie, R.J.1
Lees, A.J.2
Stern, G.M.3
-
94
-
-
0023938094
-
Duodenal and gastric delivery of levodopa in Parkinsonism
-
Kurlan R, Natl JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol 1988; 23: 589-95
-
(1988)
Ann Neurol
, vol.23
, pp. 589-595
-
-
Kurlan, R.1
Natl, J.G.2
Woodward, W.R.3
-
95
-
-
0013685763
-
Continuous duodenal infusions of levodopa: Plasma concentrations and motor fluctuations in Parkinson's disease
-
Sage JI, Schuh L, Heikkila RB, et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol 1988; 11: 36-44
-
(1988)
Clin Neuropharmacol
, vol.11
, pp. 36-44
-
-
Sage, J.I.1
Schuh, L.2
Heikkila, R.B.3
-
96
-
-
0024361116
-
The promise and limitations of controlled-release oral levodopa administration
-
Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 1989; 12: 147-66
-
(1989)
Clin Neuropharmacol
, vol.12
, pp. 147-166
-
-
Cedarbaum, J.M.1
-
97
-
-
0024850458
-
Pharmaceutical design and development of a Sinemet controlled-release formulation
-
Dempski RE, Scholtz EC, Oberholtzer HR, et al. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989; 39 Suppl. 2; 20-4
-
(1989)
Neurology
, vol.39
, Issue.2 SUPPL.
, pp. 20-24
-
-
Dempski, R.E.1
Scholtz, E.C.2
Oberholtzer, H.R.3
-
98
-
-
0023639043
-
The hydrodynamically balanced system: A novel principle of controlled drug release
-
Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Fur Neurol 1987; 27 Suppl. 2, 21-7
-
(1987)
Fur Neurol
, vol.27
, Issue.2 SUPPL.
, pp. 21-27
-
-
Erni, W.1
Held, K.2
-
99
-
-
0024804838
-
Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies
-
Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39 Suppl. 2; 25-37
-
(1989)
Neurology
, vol.39
, Issue.2 SUPPL.
, pp. 25-37
-
-
Yeh, K.C.1
August, T.F.2
Bush, D.F.3
-
100
-
-
0024829604
-
Controlled-release carbidopa/levodopa(Sinemet 50/200 CR4): Clinical and pharmacokinelic studies
-
LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa(Sinemet 50/200 CR4): clinical and pharmacokinelic studies. Neurology 1989; 39 Suppl. 2; 45-53
-
(1989)
Neurology
, vol.39
, Issue.2 SUPPL.
, pp. 45-53
-
-
LeWitt, P.A.1
Nelson, M.V.2
Berchou, R.C.3
-
101
-
-
0023629560
-
Bioavailability of L-dopa afler Madopar HBS administration in healthy volunteers
-
Crevoisier C, Hoevels H, Zurcher G, et al. Bioavailability of L-dopa afler Madopar HBS administration in healthy volunteers. Eur Neurol 1987; 27 Suppl. 1; 36-46
-
(1987)
Eur Neurol
, vol.27
, Issue.1 SUPPL.
, pp. 36-46
-
-
Crevoisier, C.1
Hoevels, H.2
Zurcher, G.3
-
102
-
-
0023616070
-
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease
-
Marion MH, Stocchi F, Malcolm SL, et al. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol 1987; 27 Suppl. 1: 54-8
-
(1987)
Eur Neurol
, vol.27
, Issue.1 SUPPL.
, pp. 54-58
-
-
Marion, M.H.1
Stocchi, F.2
Malcolm, S.L.3
-
103
-
-
0042461417
-
Therapeutic advantages of sustained release levodopa formulations in Parkinson's disease
-
Hutton JT, Morris JL. Therapeutic advantages of sustained release levodopa formulations in Parkinson's disease. CNS Drugs 1994; 2: 110-9
-
(1994)
CNS Drugs
, vol.2
, pp. 110-119
-
-
Hutton, J.T.1
Morris, J.L.2
-
104
-
-
0028473764
-
Initiating treatment for idiopathic parkinsonism
-
Calne DB. Initiating treatment for idiopathic parkinsonism. Neurology 1994; 44 (6 Suppl.). 19S-22S
-
(1994)
Neurology
, vol.44
, Issue.6 SUPPL.
-
-
Calne, D.B.1
-
105
-
-
0023694278
-
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations
-
Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology 1988; 38: 1143-6
-
(1988)
Neurology
, vol.38
, pp. 1143-1146
-
-
Goetz, C.G.1
Tanner, C.M.2
Shannon, K.M.3
-
106
-
-
0028085949
-
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients
-
Hammerstad JP, Woodward WR, Nutt JG, et al. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994; 17: 429-34
-
(1994)
Clin Neuropharmacol
, vol.17
, pp. 429-434
-
-
Hammerstad, J.P.1
Woodward, W.R.2
Nutt, J.G.3
-
107
-
-
0024847369
-
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet
-
Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet. Neurology 1989; 39 Suppl. 2; 38-44
-
(1989)
Neurology
, vol.39
, Issue.2 SUPPL.
, pp. 38-44
-
-
Cedarbaum, J.M.1
Kutt, H.2
McDowell, F.H.3
-
108
-
-
0028898323
-
Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation
-
Harder S, Baas H, Bergemann N, et al. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995; 39: 39-44
-
(1995)
Br J Clin Pharmacol
, vol.39
, pp. 39-44
-
-
Harder, S.1
Baas, H.2
Bergemann, N.3
-
109
-
-
0024520481
-
A double-blind, crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance
-
Cedarbaum JM, Hoey M, McDowell FH. A double-blind, crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989; 52: 207-12
-
(1989)
J Neurol Neurosurg Psychiatry
, vol.52
, pp. 207-212
-
-
Cedarbaum, J.M.1
Hoey, M.2
McDowell, F.H.3
-
110
-
-
0023634716
-
Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid of the absorption on Madopar HBS in volunteers
-
Malcolm SL, Allen JG, Bird H, et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid of the absorption on Madopar HBS in volunteers. Eur Neurol 1987; 27 Suppl. 1; 28-35
-
(1987)
Eur Neurol
, vol.27
, Issue.1 SUPPL.
, pp. 28-35
-
-
Malcolm, S.L.1
Allen, J.G.2
Bird, H.3
-
111
-
-
0025886192
-
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR)
-
Wilding IR, Hardy JG, Davis SS, et al. Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 1991; 14: 305-21
-
(1991)
Clin Neuropharmacol
, vol.14
, pp. 305-321
-
-
Wilding, I.R.1
Hardy, J.G.2
Davis, S.S.3
-
112
-
-
0024836303
-
Controlled-release carbidopa/levodopu (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: Clinical and pharmacokinetic observations
-
Deleu D, Jacques M, Michotte Y, et al. Controlled-release carbidopa/levodopu (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology 1989; 39 Suppl. 2; 88-92
-
(1989)
Neurology
, vol.39
, Issue.2 SUPPL.
, pp. 88-92
-
-
Deleu, D.1
Jacques, M.2
Michotte, Y.3
-
113
-
-
0026461370
-
The use of Sinemet CR in the management of mild to moderate Parkinson's disease
-
Rodnitzky RL. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Neurology 1992; 42 Suppl. 1: 44-50
-
(1992)
Neurology
, vol.42
, Issue.1 SUPPL.
, pp. 44-50
-
-
Rodnitzky, R.L.1
-
114
-
-
84951515357
-
Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease
-
Mannisto PT. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994; 1: 172-9
-
(1994)
CNS Drugs
, vol.1
, pp. 172-179
-
-
Mannisto, P.T.1
-
115
-
-
0027935135
-
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransterase
-
Kaakkola S, Gordin A, Mannislo PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransterase. Gen Pharmacol 1994; 25: 813-24
-
(1994)
Gen Pharmacol
, vol.25
, pp. 813-824
-
-
Kaakkola, S.1
Gordin, A.2
Mannislo, P.T.3
-
116
-
-
0027445460
-
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with parkinson's disease
-
Myllyla VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with parkinson's disease. Eur J Clin Pharmacol 1993; 45: 419-23
-
(1993)
Eur J Clin Pharmacol
, vol.45
, pp. 419-423
-
-
Myllyla, V.V.1
Sotaniemi, K.A.2
Illi, A.3
-
117
-
-
0028286186
-
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
-
Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913-9
-
(1994)
Neurology
, vol.44
, pp. 913-919
-
-
Nutt, J.G.1
Woodward, W.R.2
Beckner, R.M.3
-
118
-
-
0028078890
-
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
-
Kaakkola S, Teravainen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994; 44: 77-80
-
(1994)
Neurology
, vol.44
, pp. 77-80
-
-
Kaakkola, S.1
Teravainen, H.2
Ahtila, S.3
-
119
-
-
0028137620
-
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
-
Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 186-9
-
(1994)
J Neurol Neurosurg Psychiatry
, vol.57
, pp. 186-189
-
-
Merello, M.1
Lees, A.J.2
Webster, R.3
-
120
-
-
0027770982
-
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
-
Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685-8
-
(1994)
Neurology
, vol.44
, pp. 2685-2688
-
-
Roberts, J.W.1
Cora-Locatelli, G.2
Bravi, D.3
-
121
-
-
0029021182
-
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
-
Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995; 18: 258-65
-
(1995)
Clin Neuropharmacol
, vol.18
, pp. 258-265
-
-
Limousin, P.1
Pollak, P.2
Pfefen, J.P.3
-
122
-
-
0028979687
-
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: Correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement
-
Tohgi H, Abe T, Yamazaki K, et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192: 165-8
-
(1995)
Neurosci Lett
, vol.192
, pp. 165-168
-
-
Tohgi, H.1
Abe, T.2
Yamazaki, K.3
-
123
-
-
0027520391
-
Current status of dopamine agonists in Parkinson's disease management
-
Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93
-
(1993)
Drugs
, vol.46
, pp. 384-393
-
-
Montastruc, J.L.1
Rascol, O.2
Senard, J.M.3
-
124
-
-
0025938996
-
Antiparkinsonian dopamine agonists: A review of the pharmacokinetics and neuropharmacology in animals and humans
-
Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991; 3: 151-201
-
(1991)
J Neural Transm Park Dis Dement Sect
, vol.3
, pp. 151-201
-
-
Wachtel, H.1
-
126
-
-
0023775714
-
Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation
-
Drewe J, Mazer N, Abisch E, et al. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 1988; 35: 535-41
-
(1988)
Eur J Clin Pharmacol
, vol.35
, pp. 535-541
-
-
Drewe, J.1
Mazer, N.2
Abisch, E.3
-
127
-
-
0020522424
-
Fate and disposition of bromocriptine in animals and man. Pt II: Absorption, elimination and metabolism
-
Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. Pt II: absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983; 8: 51-62
-
(1983)
Eur J Drug Metab Pharmacokinet
, vol.8
, pp. 51-62
-
-
Maurer, G.1
Schreier, E.2
Delaborde, S.3
-
128
-
-
0025931590
-
The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine
-
Kopitar Z, Vrhovac B, Povsic L, et al. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet 1991; 16: 177-81
-
(1991)
Eur J Drug Metab Pharmacokinet
, vol.16
, pp. 177-181
-
-
Kopitar, Z.1
Vrhovac, B.2
Povsic, L.3
-
129
-
-
0023809080
-
Therapeutic applications of bromocriptine in endocrine and neurological diseases
-
Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67-82
-
(1988)
Drugs
, vol.36
, pp. 67-82
-
-
Ho, K.Y.1
Thorner, M.O.2
-
130
-
-
0021927474
-
Pharmacokinetic interactions of the macrolide antibiotics
-
Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79
-
(1985)
Clin Pharmacokinet
, vol.10
, pp. 63-79
-
-
Ludden, T.M.1
-
131
-
-
0025324182
-
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
-
Nelson MV, Berchou RC, Kareli D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694-7
-
(1990)
Clin Pharmacol Ther
, vol.47
, pp. 694-697
-
-
Nelson, M.V.1
Berchou, R.C.2
Kareli, D.3
-
132
-
-
0017033806
-
Bromocriptine in Parkinsonism: Long-term treatment, dose response, and comparison with levodopa
-
Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976; 39: 1101-8
-
(1976)
J Neurol Neurosurg Psychiatry
, vol.39
, pp. 1101-1108
-
-
Parkes, J.D.1
Debono, A.G.2
Marsden, C.D.3
-
133
-
-
0020030491
-
Bromocriptine: Low-dose therapy in Parkinson disease
-
Teychenne PF, Bergsrud D, Racy A, et al. Bromocriptine: low-dose therapy in Parkinson disease. Neurology 1982; 32: 577-83
-
(1982)
Neurology
, vol.32
, pp. 577-583
-
-
Teychenne, P.F.1
Bergsrud, D.2
Racy, A.3
-
134
-
-
0021827869
-
Low-dose bromocriptine therapy in Parkinson's disease
-
Pfeiffer RF, Wilken K, Glaeske C, et al. Low-dose bromocriptine therapy in Parkinson's disease. Arch Neurol 1985; 42: 586-8
-
(1985)
Arch Neurol
, vol.42
, pp. 586-588
-
-
Pfeiffer, R.F.1
Wilken, K.2
Glaeske, C.3
-
135
-
-
0023032395
-
Domperidone and Parkinson's disease
-
Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9: 517-32
-
(1986)
Clin Neuropharmacol
, vol.9
, pp. 517-532
-
-
Parkes, J.D.1
-
136
-
-
0018395712
-
Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease
-
Agid Y, Pollak P, Bonnet AM, et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979; 1: 570-2
-
(1979)
Lancet
, vol.1
, pp. 570-572
-
-
Agid, Y.1
Pollak, P.2
Bonnet, A.M.3
-
138
-
-
0019467050
-
Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level
-
Humpel M, Nieuweboer B, Hasan SH, et al. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level. Eur J Clin Pharmacol 1981; 20: 47-51
-
(1981)
Eur J Clin Pharmacol
, vol.20
, pp. 47-51
-
-
Humpel, M.1
Nieuweboer, B.2
Hasan, S.H.3
-
140
-
-
0025317247
-
Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease
-
Langtry HD, Clissold SP. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506
-
(1990)
Drugs
, vol.39
, pp. 491-506
-
-
Langtry, H.D.1
Clissold, S.P.2
-
142
-
-
0025880115
-
Absorption of apomorphine by various routes in Parkinsonism
-
Gancher ST, Null JG, Woodward WR. Absorption of apomorphine by various routes in Parkinsonism. Mov Disord 1991; 6: 212-6
-
(1991)
Mov Disord
, vol.6
, pp. 212-216
-
-
Gancher, S.T.1
Null, J.G.2
Woodward, W.R.3
-
143
-
-
0024378094
-
Peripheral pharmacokinetics of apomorphine in humans
-
Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-8
-
(1989)
Ann Neurol
, vol.26
, pp. 232-238
-
-
Gancher, S.T.1
Woodward, W.R.2
Boucher, B.3
-
145
-
-
0029002551
-
Apomorphine pharmacokinetics in Parkinsonism alter intranasal and subcutaneous application
-
Sam E, Jeanjean AP, Maloteaux JM, et al. Apomorphine pharmacokinetics in Parkinsonism alter intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995; 20: 27-33
-
(1995)
Eur J Drug Metab Pharmacokinet
, vol.20
, pp. 27-33
-
-
Sam, E.1
Jeanjean, A.P.2
Maloteaux, J.M.3
-
146
-
-
0025793247
-
Intranasal apomorphine in Parkinson's disease
-
Kleedorfer B, Turjanski N, Ryan R, et al. Intranasal apomorphine in Parkinson's disease. Neurology 1991; 41: 761-2
-
(1991)
Neurology
, vol.41
, pp. 761-762
-
-
Kleedorfer, B.1
Turjanski, N.2
Ryan, R.3
-
148
-
-
0026750666
-
Intranasal apomorphine in parkinsonian on-off fluctuations
-
Van Laar T, Jansen ENH, Essink AWG, et al. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992; 49: 482-4
-
(1992)
Arch Neurol
, vol.49
, pp. 482-484
-
-
Van Laar, T.1
Jansen, E.N.H.2
Essink, A.W.G.3
-
149
-
-
0025888372
-
Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations
-
Hughes AJ, Webster R, Bovingdon M, et al. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin Neuropharmacol 1991; 14: 556-61
-
(1991)
Clin Neuropharmacol
, vol.14
, pp. 556-561
-
-
Hughes, A.J.1
Webster, R.2
Bovingdon, M.3
-
150
-
-
0026009886
-
Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease
-
Durif F, Jeanneau E, Serre-Deheauvais F, et al. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 493-4
-
(1991)
Eur J Clin Pharmacol
, vol.41
, pp. 493-494
-
-
Durif, F.1
Jeanneau, E.2
Serre-Deheauvais, F.3
-
151
-
-
0029018469
-
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories
-
Van Laar T, Jansen ENH, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10: 433-9
-
(1995)
Mov Disord
, vol.10
, pp. 433-439
-
-
Van Laar, T.1
Jansen, E.N.H.2
Neef, C.3
-
153
-
-
0027264828
-
Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
-
Hughes AJ, Bishop S, Kleedorler B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-70
-
(1993)
Mov Disord
, vol.8
, pp. 165-170
-
-
Hughes, A.J.1
Bishop, S.2
Kleedorler, B.3
-
155
-
-
0021687731
-
Biperiden effects and plasma levels in volunteers
-
Hollmann M, Brode E, Greger G, et al. Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 1984; 27: 619-21
-
(1984)
Eur J Clin Pharmacol
, vol.27
, pp. 619-621
-
-
Hollmann, M.1
Brode, E.2
Greger, G.3
-
156
-
-
0022639883
-
Pharmacokinetic and pharmacodynamic studies following intravenous and oral administration of the antiparkinsonian drug biperiden in normal subjects
-
Grimaldi R, Perucca E, Ruberto G, et al. Pharmacokinetic and pharmacodynamic studies following intravenous and oral administration of the antiparkinsonian drug biperiden in normal subjects. Eur J Clin Pharmacol 1986; 30: 735-7
-
(1986)
Eur J Clin Pharmacol
, vol.30
, pp. 735-737
-
-
Grimaldi, R.1
Perucca, E.2
Ruberto, G.3
-
158
-
-
0021838295
-
Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients
-
Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18: 35-40
-
(1985)
Ann Neurol
, vol.18
, pp. 35-40
-
-
Burke, R.E.1
Fahn, S.2
-
159
-
-
0020517955
-
Comparaison pharmacoclinique de deux formes galeniques de trihexyphenidyle
-
Garbarg S, Devissaguet JP, Prost M, et al. Comparaison pharmacoclinique de deux formes galeniques de trihexyphenidyle. Encéphale 1983; IX: 167-74
-
(1983)
Encéphale
, vol.9
, pp. 167-174
-
-
Garbarg, S.1
Devissaguet, J.P.2
Prost, M.3
-
160
-
-
0029054209
-
Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans
-
He H, McKay G, Wirshing B, et al. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. J Pharm Sci 1995; 84: 561-7
-
(1995)
J Pharm Sci
, vol.84
, pp. 561-567
-
-
He, H.1
McKay, G.2
Wirshing, B.3
-
161
-
-
0019774915
-
Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloridein man
-
Labout JJM, Thijssen CT, Keijser GGJ, et al. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloridein man. Eur J Clin Pharmacol 1982; 21: 343-50
-
(1982)
Eur J Clin Pharmacol
, vol.21
, pp. 343-350
-
-
Labout, J.J.M.1
Thijssen, C.T.2
Keijser, G.G.J.3
-
162
-
-
0020554474
-
Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-n-desmethylorphenadrine (Tofenacine) in the rat
-
Bast A, van Kemenade FAA, Savenije-Chapel EM, et al. Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-n-desmethylorphenadrine (Tofenacine) in the rat. Res Commun Chem Pathol Pharmacol 1983; 40: 391-403
-
(1983)
Res Commun Chem Pathol Pharmacol
, vol.40
, pp. 391-403
-
-
Bast, A.1
Van Kemenade, F.A.A.2
Savenije-Chapel, E.M.3
-
163
-
-
0024319135
-
Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics
-
Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 1989; 35: 736-43
-
(1989)
Mol Pharmacol
, vol.35
, pp. 736-743
-
-
Reidy, G.F.1
Mehta, I.2
Murray, M.3
-
165
-
-
0015272059
-
Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: A comparison of eight mammalian species
-
Squires RF. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972; 5: 355-70
-
(1972)
Adv Biochem Psychopharmacol
, vol.5
, pp. 355-370
-
-
Squires, R.F.1
-
166
-
-
0017594522
-
Dopamine is a monoamine oxidase-B substrate in man
-
Glover V, Sandler M, Owen F, et al. Dopamine is a monoamine oxidase-B substrate in man. Nature 1977; 265: 80-1
-
(1977)
Nature
, vol.265
, pp. 80-81
-
-
Glover, V.1
Sandler, M.2
Owen, F.3
-
167
-
-
0026841329
-
Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms
-
Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms.' Neurology 1991; 42 Suppl. 4; 13-26
-
(1991)
Neurology
, vol.42
, Issue.4 SUPPL.
, pp. 13-26
-
-
Olanow, C.W.1
Calne, D.2
-
169
-
-
0010476575
-
Pharmacokinetics of l-deprenyl and N-desmethyldeprenyl in blood versus plasma after single dose oral administration of 10 mg of selegiline
-
Michaelis K, Waitzinger J, Agvaz U, et al. Pharmacokinetics of l-deprenyl and N-desmethyldeprenyl in blood versus plasma after single dose oral administration of 10 mg of selegiline. Pharmacol Res 1993; 10: S331
-
(1993)
Pharmacol Res
, vol.10
-
-
Michaelis, K.1
Waitzinger, J.2
Agvaz, U.3
-
170
-
-
0022638352
-
Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency
-
Yoshida T, Yamada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986; 16: 129-36
-
(1986)
Xenobiotica
, vol.16
, pp. 129-136
-
-
Yoshida, T.1
Yamada, Y.2
Yamamoto, T.3
-
171
-
-
0020085133
-
Metabolism of (-) deprenyl to amphetamine and methamphetamme may be responsible for deprenyl's therapeutic benefit: A biochemical assessment
-
Karoum F, Chuang LW, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and methamphetamme may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 1982; 32: 503-9
-
(1982)
Neurology
, vol.32
, pp. 503-509
-
-
Karoum, F.1
Chuang, L.W.2
Eisler, T.3
-
172
-
-
0028593637
-
Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies
-
Yasar S, Bergman J. Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 1994; 56: 768-73
-
(1994)
Clin Pharmacol Ther
, vol.56
, pp. 768-773
-
-
Yasar, S.1
Bergman, J.2
-
173
-
-
0023784118
-
Deprenyl as symptomatic therapy in Parkinson's disease
-
Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11: 387-400
-
(1988)
Clin Neuropharmacol
, vol.11
, pp. 387-400
-
-
Golbe, L.I.1
-
174
-
-
0027981209
-
Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal
-
Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal. Synapse 1994; 18: 86-93
-
(1994)
Synapse
, vol.18
, pp. 86-93
-
-
Fowler, J.S.1
Volkow, N.D.2
Logan, J.3
-
176
-
-
0025195904
-
Possible interactions between deprenyl and Prozac
-
Suchowersky O, deVries J. Possible interactions between deprenyl and Prozac. Can J Neurol Sci 1990; 17: 352-3
-
(1990)
Can J Neurol Sci
, vol.17
, pp. 352-353
-
-
Suchowersky, O.1
DeVries, J.2
-
177
-
-
0027500494
-
Pseudophaeo-chromocytoma in parkinsonian patient treated with fluoxetine plus selegiline
-
Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeo-chromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet 1993; 341: 555
-
(1993)
Lancet
, vol.341
, pp. 555
-
-
Montastruc, J.L.1
Chamontin, B.2
Senard, J.M.3
-
179
-
-
0025869797
-
The serotonin syndrome
-
Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
-
(1991)
Am J Psychiatry
, vol.148
, pp. 705-713
-
-
Sternbach, H.1
-
180
-
-
0024456653
-
Effect of deprenyl on the progression of disability in early Parkinson's disease
-
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
-
(1989)
N Engl J Med
, vol.321
, pp. 1364-1371
-
-
-
181
-
-
0024343466
-
The effect of deprenyl (selegiline) on the natural history of parkinson's disease
-
Tetrad JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of parkinson's disease. Science 1989; 245: 519-22
-
(1989)
Science
, vol.245
, pp. 519-522
-
-
Tetrad, J.W.1
Langston, J.W.2
-
182
-
-
0026596575
-
Selegiline as initial treatment in de novo parkinsonian patients
-
Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339-43
-
(1992)
Neurology
, vol.42
, pp. 339-343
-
-
Myllyla, V.V.1
Sotaniemi, K.A.2
Vuorinen, J.A.3
-
183
-
-
0025189747
-
L-deprenyl, levodopu pharmacokinetics, and response fluctuations in Parkinson's disease
-
Cedarbaum JM, Silvestri M, Clark M, et al. L-deprenyl, levodopu pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmaeol 1990; 13: 29-35
-
(1990)
Clin Neuropharmaeol
, vol.13
, pp. 29-35
-
-
Cedarbaum, J.M.1
Silvestri, M.2
Clark, M.3
-
184
-
-
84996113682
-
Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis
-
Teychenne PF, Parker S. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis. Acta Neurol Scand 1989; 126: 119-25
-
(1989)
Acta Neurol Scand
, vol.126
, pp. 119-125
-
-
Teychenne, P.F.1
Parker, S.2
-
185
-
-
0026623522
-
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging
-
Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541-4
-
(1992)
Neurology
, vol.42
, pp. 541-544
-
-
Baronti, F.1
Davis, T.L.2
Boldry, R.C.3
-
186
-
-
0019124920
-
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa
-
Schachter M, Marsden CD, Parkes JD, et al. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980; 43: 1016-21
-
(1980)
J Neurol Neurosurg Psychiatry
, vol.43
, pp. 1016-1021
-
-
Schachter, M.1
Marsden, C.D.2
Parkes, J.D.3
-
187
-
-
0021852048
-
The effect of L-deprenyl on on-off phenomena in Parkinson's disease
-
Brodersen P, Philbert A, Gulliksen G, et al. The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand 1985; 71: 494-7
-
(1985)
Acta Neurol Scand
, vol.71
, pp. 494-497
-
-
Brodersen, P.1
Philbert, A.2
Gulliksen, G.3
-
188
-
-
3242784708
-
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
-
Golbe LI, Lieherman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45-55
-
(1988)
Clin Neuropharmacol
, vol.11
, pp. 45-55
-
-
Golbe, L.I.1
Lieherman, A.N.2
Muenter, M.D.3
-
189
-
-
0026529661
-
Deprenyl in Parkinson's disease: Mechanisms, neuroprolective effect, indications and adverse effects
-
Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprolective effect, indications and adverse effects. Can J Neurol Sci 1992; 19: 142-6
-
(1992)
Can J Neurol Sci
, vol.19
, pp. 142-146
-
-
Vezina, P.1
Mohr, E.2
Grimes, D.3
-
190
-
-
0014684012
-
Amantadine in the treatment of Parkinson's disease
-
Schwah RS, England Jr AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208: 1168-70
-
(1969)
JAMA
, vol.208
, pp. 1168-1170
-
-
Schwah, R.S.1
England Jr., A.C.2
Poskanzer, D.C.3
-
191
-
-
0026005169
-
N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease
-
Greenamyre JT, O'Brien CF. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991; 48: 977-81
-
(1991)
Arch Neurol
, vol.48
, pp. 977-981
-
-
Greenamyre, J.T.1
O'Brien, C.F.2
-
192
-
-
0021795615
-
Amantadine kinetics in healthy elderly men: Implications for influenza prevention
-
Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 1985; 37: 137-44
-
(1985)
Clin Pharmacol Ther
, vol.37
, pp. 137-144
-
-
Aoki, F.Y.1
Sitar, D.S.2
-
193
-
-
0019475566
-
Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function
-
Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 94: 454-8
-
(1981)
Ann Intern Med
, vol.94
, pp. 454-458
-
-
Horadam, V.W.1
Sharp, J.G.2
Smilack, J.D.3
-
195
-
-
0026353743
-
Comparison of pharmacokinetic and safety profiles of amanladine 50- And 100-mg daily doses in elderly nursing home residents
-
Somani SK, Degelau J, Cooper SL, et al. Comparison of pharmacokinetic and safety profiles of amanladine 50- and 100-mg daily doses in elderly nursing home
-
(1991)
Pharmacotherapy
, vol.11
, pp. 460-466
-
-
Somani, S.K.1
Degelau, J.2
Cooper, S.L.3
-
196
-
-
0029019640
-
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results
-
Gerlach M, Riederer P, Youdim MBH. Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochem Pharmacol 1995; 50: 1-16
-
(1995)
Biochem Pharmacol
, vol.50
, pp. 1-16
-
-
Gerlach, M.1
Riederer, P.2
Youdim, M.B.H.3
|